May 10, 2017 / 6:05 AM / 3 months ago

BRIEF-Karo Pharma Q1 core profit rose to SEK 44 mln

May 10 (Reuters) - Karo Pharma Ab:

* Q1 EBITDA amounted to MSEK 43.7 (9.3)

* Q1 net sales amounted to MSEK 139.3 (82.3), growth was mainly due to acquisitions Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below